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TISSUE ENGINEERING AND GROWTH FACTORS: UPDATED EVIDENCE 
Parichehr Hassanzadeh 
Nanomedicine and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, 
Tehran, Iran 
In difficult-to-treat disorders, the traditional pharmacological agents or medical devices alleviate the symptoms but do not re-
verse the condition. In recent years, the increasing interest into the field of tissue engineering has generated different strategies 
for tissue growth in vitro or the enhanced repair of damaged tissues in vivo. The core approach of tissue engineering for either 
therapeutic or diagnostic applications is the ability to exploit living cells in a variety of ways. In this context, identification of 
the ideal cells and development of biomaterials including the scaffolds for potential applications in the repair, replacement, or 
regeneration of damaged tissues appear crucial. Meanwhile, successful tissue engineering is often dependent on the delivery of 
growth factors to the regenerating tissues. Growth factors are multifunctional peptides which play fundamental roles in a wide 
variety of physiological processes including cell proliferation, chemotaxis, intercellular signalling, angiogenesis and the formation 
of extracellular matrix, also the re-establishment of tissue integrity. In order to mimic the endogenous profile of growth factor 
production during the natural tissue morphogenesis or regeneration, the sophisticated mechanisms of growth factor delivery 
should be developed. This review highlights the general aspects of tissue engineering along with the approaches taken to incor-
porate growth factors within the biomaterials and their delivery to injured tissue. Biomed Rev 2012; 23: 19-35.
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INTRODUCTION
There are a wide variety of diseases with the multiple symp-
toms and disabilities as well as the complexity of biomolecular 
and signalling cascades; they represent intricate challenges 
towards the development of therapy strategies. For example, 
treatment of central nervous system (CNS) disorders is one 
of the most challenging and complex areas of medicine. Cell 
loss following the neural insults disrupts the connectivity and 
signal transmission between the neurons leading to neuronal 
dysfunction. Traumatic injuries to the CNS including the 
traumatic brain injury (TBI) and spinal cord injury (SCI) re-
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sult in axonal degeneration and neuronal necrosis. Following 
SCI, the victims are usually left paralyzed and only palliative 
measures are available. In TBI, pharmacological agents reduce 
the sequelae in the acute phase of the injury process or enhance 
the function of remaining brain tissue during the chronic stage 
but do not lead to the regeneration or replacement of damaged 
or necrotic nervous tissue. In general, the adult brain has a 
limited regenerative capacity and TBI or stroke results in a 
usually permanent neuronal loss and the disruption of brain 
parenchyma. Since SCI and TBI are multifactorial in patho-
physiology, therefore, it is likely that the effective treatments 
require the combinations of strategies to counteract secondary 
injuries as well as the methods to enhance axonal re-growth, 
synaptic plasticity, and inhibition of astrocytosis (1,2). Cur-
rent treatment strategies against neurodegenerative disorders 
focus on the minimizing of further tissue loss and/or alleviat-
ing symptoms through the administration of pharmacological 
agents, rehabilitation, or surgical intervention.  However, 
these treatments usually mitigate the degeneration process 
and do not reverse the condition (3). In addition, blood-brain 
barrier (BBB) hampers the entrance of hydrophilic drugs or 
large molecules into the brain (4). Therefore, drug delivery 
to the CNS is a main challenge in the field of regenerative 
medicine (5). The first approach to treat CNS diseases has 
been based on the invasive techniques of neurosurgery that 
deliver the drug directly to the target site (6). This method, 
besides the neurosurgical costs, is associated with the increased 
risk of infections and low patient compliance. In addition, a 
temporary chemical or physical disruption of the BBB, or an 
osmotic shift may be used to allow the drug to cross the BBB 
(7). However, the temporary disruption of the BBB results in 
several drawbacks such as a physiological stress or a transient 
increase in intracranial pressure. Furthermore, the increase of 
BBB permeability, even for a short time, makes the brain vul-
nerable to the infections. Hence, non-invasive techniques based 
on the modifications of physicochemical properties of drugs 
or conjugation of molecules with antibodies are suggested to 
improve drug delivery to the brain (8,9). The peripheral nerv-
ous system (PNS) is more accessible than the CNS, however, 
problems are still encountered mainly due to the poor stability 
and considerable side effects of many neuroactive compounds 
when administered systemically. Artificial transplants or trans-
planted organs have been used for incurable end-stage diseases 
or tissue loss for a long time. Such interventions are expected 
to be challenged by the necessity of lifelong immunosuppres-
sion or other complications.
In recent years, tissue engineering, a major component of 
regenerative medicine, has emerged as a rapidly expanding 
approach to revolutionize the ways for improving patients’ 
quality of life through restoring, maintaining, or enhancing 
tissue function. In the post-injury brain, tissue engineering 
represents several advantages over the pharmacological 
strategies such as the ability to bridge the structural gaps for 
reconnection of neuronal processes or eliciting specific cell 
behaviour. In addition, guided neurite and axonal growth 
ensures the appropriate and regulated connectivity within 
the neural circuitry of brain (10). In neurological disorders, 
successful cell therapies to replace lost neurons or prevent 
further degeneration are underpinned by several mechanisms 
including the vascularization, providing of cellular microen-
vironments for neural regeneration, and promotion of guided 
axonal outgrowth. These factors act cumulatively to enhance 
cell survival and connectivity, and re-establish a functional 
neuronal network (11).
In addition to the therapeutic applications, tissue engineer-
ing is used for diagnostic screening, e.g., a tissue is made in 
vitro and used for the evaluation of a drug toxicity or phar-
macokinetic profile (12). Since the growth factors play an 
essential role in tissue repair and healing, the incorporate of 
these multifunctional proteins within the biomaterials as well 
as the their delivery systems will be discussed in further parts 
of this manuscript.
TISSUE ENGINEERING: THE GENERAL ASPECTS  
As indicated, tissue engineering is a rapidly developing inter-
disciplinary field that is characterized by the convergence of 
disciplines such as advanced material science, biochemistry, 
cell biology, engineering, and medicine. Tissue engineering 
includes substitutive (whole organ replacement), histioconduc-
tive (replacement of missing or damaged parts of an organ 
with ex vivo constructs), and histioinductive (facilitation of 
self-repair or gene therapy) approaches (13). In general, the 
goal of tissue engineering is to regenerate tissues and restore 
organ function through the implantation of cells or incorpora-
tion of matrices. Human tissue engineering offers tremendous 
promise for the improved prognosis and treatment, faster 
recovery, and a more biologically favourable situation that 
may facilitate the self-healing of body. 
Medical applications of tissue engineering
These will be briefly listed below and will be further discussed 
in another section of the present review.
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Tissue-engineered bone
The regeneration of skeletal bone may be a major clinical 
need for victims of the accidents or degenerative diseases. 
Development of new biomimetic materials which provide a 
suitable microenvironment for cell-matrix interaction as well 
as the proliferation of differentiated osteocytes have been the 
focus of intense research (14). 
Tissue-engineered cartilage 
Degenerative joint conditions become increasingly common with 
age, however, damage may also occur in young patients. Conven-
tional treatments include partial or total joint replacements, but 
at present, the damaged cartilage may be replaced with a tissue 
engineered cartilage using the patient’s own chondrocytes (15). 
Tissue-engineered myocardium
There is a number of research projects aimed at regenerating 
or repairing the myocardium including the development of 
tissue-engineered myocardial patches (16). 
Tissue-engineered peripheral nerves
When a peripheral nerve is severed, the remaining gap in the 
nerve ending may be too wide to be treated by the conventional 
microsurgery. Hence, a growing interest has been attracted 
towards the identification of suitable biomaterials that may 
provide a conduit to enable regeneration-promoting Schwann 
cells to grow in a guided manner to bridge the gaps (17).
Tissue-engineered skin
Cells which have been grown on a variety of substrates provide 
a biocompatible physical barrier against the fluid loss and in-
fection. They may be used for the treatment of serious burns 
and diabetic ulcers or promote the regeneration of patient’s 
own skin (18). 
Tissue-engineered blood vessels
Development of tissue-engineered blood vessels is one of the 
most exciting current challenges in reconstructive medicine. A 
variety of approaches are being developed using both synthetic 
biopolymer scaffolds and biologically-derived matrix materi-
als that entail the incorporation of smooth muscle cells and 
vascular endothelial cells into a tubular scaffold in order to 
provide a structure similar to that of a native artery. Meanwhile, 
an appropriate respond to the changes of blood pressure is a 
particularly important characteristic for the tissue-engineered 
blood vessels (19). 
Tissue-engineered cornea
Since the cornea is avascular, therefore, tissue engineering of 
cornea is a major medical challenge. In this sense, the selec-
tion of the corneal cells, the effects of growth factors on the 
culture of corneal cells, and the application of suitable scaffolds 
appear particularly crucial (20).
Research areas in tissue engineering
Tissue engineering includes the following research areas:  (i) 
biomolecules; including the differentiation factors, growth 
factors, and other key proteins, (ii) biomaterials; which may 
influence the organization, growth, and differentiation of cells 
in the process of formation of a desired tissue, (iii) cells; which 
may be autologous, allogeneic, xenogeneic, or stem cells, 
(iv) safety and performance; including the characteristics 
of tissues and identification of the properties required for 
the engineered tissues, (v) manufacturing issues; such as 
cell expansion or storage,  and three-dimensional (3D) tissue 
growth, and (vi) other aspects; including modelling, informat-
ics, clinical data, and quality assurance (21).
The required criteria for an effective tissue 
engineering
A number of criteria should be satisfied in order to achieve an 
effective and long-lasting repair of damaged tissues such as (i) 
the production of an adequate number of cells in order to fill 
the defect, (ii) the differentiation of the cells into the desired 
phenotype, (iii) the produced cells should be structurally and 
mechanically compliant with native cells in order to overcome 
the risk of immunological rejection, and (iv) the specialized 
cells should adopt an appropriate 3D structural support and 
secret the extracellular matrix (22).
Devices in tissue engineering
There are several types of devices such as (i) implant; a kind 
of medical device that restores or modifies the tissue func-
tion. The surface of an implant which contacts the body may 
be made of a biomedical material such as silicone, apatite, or 
titanium. Some implants such as the artificial pacemaker or 
cochlear implants contain electronic components and some 
others are consisted of bioactive substances such as the im-
plantable pills or drug-eluting stents (23), (ii) bioreactor; a 
device which provides a physiological environment in order 
to promote cell or tissue growth. The bioreactors are designed 
to perform at least one of the following functions: a) promot-
ing the uniform cell distribution, b) maintaining the desired 
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concentration of gases in the medium, c) regulation of mass 
transport of nutrients to the tissue, d) exposing tissue to physi-
cal stimuli, or e) facilitating the formation of a 3D tissue (24). 
Tissue engineering technologies are based on the biological 
triad of cells, signalling mechanisms, and extracellular matrix. 
In order to simulate the development of tissues in vitro, tissue 
engineering aims to optimize cell growth by providing regula-
tory signals in the form of growth factors and a regeneration 
template in the form of scaffold. Bioreactors may be used as 
an alternative to or in conjunction with growth factors in the 
signalling part of the triad (25), (iii) polymer matrix which 
controls tissue regeneration or wound healing and serves as a 
scaffold to support cell transplantation. Degradable polymers 
such as poly(glycolic acid) (PGA), poly(lactic acid) (PLA), 
poly(lactic-co-glycolic acid) (PLGA) and poly(e-caprolactone) 
(PCL) are used in surgical sutures, reconstructive implants, 
and drug delivery devices (26,27). PGA/PLA and copolymers 
have been widely used in artificial skin grafts for surgical repair 
of skin defects in plastic and reconstructive surgery (28). In 
addition, PGA tubes have been successfully used as guidance 
channels for axonal reconnection in human PNS injuries (29). 
Through the incorporation into the polymeric devices, protein 
structure and biological activity can be stabilized and the 
length of time over which the polypeptides or growth factors 
are released at the delivery site, is prolonged. The duration of 
drug release from a polymer matrix depends on polymer type, 
drug loading percentage, and the processing conditions (30).
 
Delivery systems in tissue engineering
In tissue engineering, the delivery systems are designed in a 
variety of configurations and geometries. They are fabricated 
from different types of natural or synthetic degradable or non-
degradable polymers which control the release of drugs or 
bioactive proteins for extended periods of time. In recent years, 
particle-based delivery systems have attracted a considerable 
interest because the engineered particles provide advantages 
in many aspects of drug delivery such as improvement of the 
solubility of poorly water-soluble compounds, prolonging 
the half-life of therapeutic agents in blood circulation, and 
delivering a drug locally or in a targeted manner to minimize 
side effects (31). In order to improve drug delivery to the 
brain, non-invasive techniques including the nanosystems or 
colloidal carriers that are lipid- or polymer-based have been 
developed (32,33). Among the colloidal carriers, polymeric 
nanoparticles are promising candidates for CNS drug deliv-
ery. These nanoparticles encapsulate the drugs and protect 
them against the excretion or metabolism within the body. 
Moreover, they deliver therapeutic agents across the BBB 
without inflicting any damage to the barrier. Application of 
polymeric nanoparticles or waxes is one of the most promis-
ing strategies for specific and selective CNS drug delivery. 
In this context, different polymers including polylactide-
co-glycolide (PLGA), chitosan, poly(butylcyanoacrilate) 
(PBCA) and poly(cyanoacrylate-co-hexadecylcyanoacrylate) 
(PHDCA) have been used to prepare nanoparticles (34). In ad-
dition, BBB permeabilizers, genetically engineered cells, and 
biodegradable or non-biodegradable polymeric devices have 
been developed in order to provide a continuous delivery of 
neuroactive agents (35,36). 
Key materials for the development of a living 
construct
The major principle of tissue engineering is based on the 
combination of living cells with a natural or synthetic sup-
port in order to build a 3D construct which is structurally and 
functionally similar to the tissue that is to be replaced. The 
development of such a construct requires the selection of four 
key materials: (i) scaffold, a 3D tissue structure that guides 
the organization, growth, and differentiation of the cells. 
Scaffolds should be biocompatible and satisfy the biological 
requirements of a specific cell population. In this context, a 
biofunctionalized hybrid scaffold which plays a crucial role in 
the repair of damaged tissue(s), is obtained by the attachment 
of biomolecules such as the growth factors which direct cell 
development and proliferation (37). In recent years, a variety 
of scaffolds have been engineered to provide an artificial 
microenvironment for the enhancement of cell survival and 
proliferation as well as the regeneration of damaged tissues. 
In general, an individualistic or disease-based approach is es-
sential for the suitable scaffolding, e.g., for a successful nerve 
regeneration, a tissue-engineered scaffold should provide both 
mechanical support for growing nerves and biological signals 
to direct the axonal growth cone to the distal stump. For brain 
repair, an increasing interest has been attracted towards the 
construction of scaffolds and optimization of their biochemical 
or biophysical properties (38,39), (ii) extracellular matrix 
which should be capable of providing optimal conditions 
for cell adhesion, growth, and differentiation within the con-
struct. This may be achieved by creating a system capable of 
controlling environmental factors such as pH, temperature, 
oxygen, and mechanical forces (40), (iii) cells; development 
of a viable construct involves a suitable supply of cells that 
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are non-immunogenic, highly proliferative, easy to harvest, 
and being able to differentiate into a variety of specialized 
cells. Efforts are now being undertaken for engineering dif-
ferent tissues and organs using the stem cells, in particular the 
mesenchymal stem cells which differentiate into a variety of 
tissues (41,42), and (iv) growth factors  (see below).
GROWTH FACTORS: THE GENERAL ASPECTS 
The term growth factor is generally used to indicate a naturally 
occurring substance which is able to stimulate cellular growth, 
proliferation, and differentiation (43). During the natural 
regeneration of tissues, there is an orchestrated delivery of 
growth factors. For example, as soon as the blood vessels are 
disrupted after wound formation, platelets enter the wound 
in great numbers and release several growth factors includ-
ing platelet-derived growth factor (PDGF) and transforming 
growth factor-β1 (TGF-β1) (44). These growth factors are 
chemotactic for a number of cell types such as macrophages, 
fibroblasts, and endothelial cells which play a critical role in 
the repair process. During the proliferative phase of wound 
repair, several growth factors including vascular endothe-
lial growth factor (VEGF), fibroblast growth factors (FGFs), 
PDGF and TGF-β isoforms provide a potent stimulus for 
fibroblasts to synthesize the key extracellular components, 
i.e., collagens, proteoglycans, fibronectin, and elastin. In the 
later stages of wound repair, growth factors are implicated in 
tissue remodelling. As the growth factors are critical for the 
maintenance of tissue integrity and cell to cell communication, 
their activities are preserved following the wound closure or 
tissue remodelling (45). 
Neurotrophins
Neurotrophins, a unique family of growth factors, play a key 
role in the connectivity and survival of neurons, the nerve 
growth factor (NGF) being prototypic member of the family 
(see Homage to Rita Levi-Montalcini in this volume of Bio-
medical Reviews). The cellular effects of neurotrophins are 
mediated by their affinity to two different receptors: the Trk 
receptor tyrosine kinase (TrkA-C) and p75 pan-neurotrophin 
receptor (p75NTR) as well as the downstream signalling cas-
cades (46,47). Neurotrophins (NGF, BDNF, NT-3, NT-4/5, NT-
6) regulate numerous neuronal functions and are implicated in 
the pathophysiology of a wide variety of neurodegenerative 
and psychiatric disorders (48-50). The therapeutic potential of 
NGF in SCI and Alzheimer’s disease as well as its involve-
ment in the molecular mechanisms of cardiometabolic and 
autoimmune diseases has been reported (51-55). In addition 
to its neurotrophic effects, NGF improves glucose and lipid 
metabolism and control energy balance and feeding behav-
iour, indicating its metabotrophic potential (56). Based on 
our previous reports, NGF is implicated in the mechanism of 
action of NK receptor antagonists, psychotropic drugs, and 
the natural compound curcumin (57-60). Other neurotrophic 
factors are more widely expressed in the CNS. Brain-derived 
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) are 
highly expressed in cortical and hippocampal structures and 
have been linked to the survival and functioning of multiple 
neuronal populations. They also mediate higher-order activi-
ties such as learning and memory (61,62).  In animal models 
of Parkinson’s disease, Huntingson’s disease, and TBI, glial-
derived neurotrophic factor (GDNF) and BDNF promote 
cell survival and integration and enhance the success of cell 
replacement therapy (63-65). As previously reported, BDNF 
and GDNF promoted the survival of axotomized rat moto-
neurons when administered simultaneously (66). Meanwhile, 
cerebrolysin is the only drug available for clinical use which 
is a mixture of different neurotrophic factors including NGF, 
BDNF, GDNF, and ciliary neurotrophic factor (CNTF). Several 
studies have demonstrated cerebrolysin-induced neuroprotec-
tion, neuroplasticity and neurogenesis (67-70). However, the 
short half-life, relatively large size, slow tissue penetration, 
and toxicity are the problems encountered in the conventional 
routes of administration of growth factors. Administration of 
insulin-like growth factor (IGF) or human growth hormone 
(hGH) poses many problems owing to their limited oral bio-
availability and short in vivo half-lives (71). Clinical trials 
using CNTF have yielded disappointing outcomes because 
of the side effects (72). Therefore, an improved growth fac-
tor delivery is essential to get a better efficacy profile. The 
bioengineered products deliver growth factors in appropriate 
concentration that has been proved difficult to achieve with 
systemic application (73). 
Growth factors and tissue engineering  
Based on the critical role of growth factors in tissue devel-
opment and repair, these multifunctional peptides should be 
involved in the tissue engineering strategies (74). One par-
ticular area that represents an exciting challenge in the field of 
tissue engineering is the repair and regeneration of cartilage. 
In this respect, cells for the generation of tissue, a scaffold to 
support the growth, and a growth factor to stimulate the cor-
rect biological signals for tissue growth and integration with 
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native cartilage are the necessary components (75,76). TGF, 
FGF, and IGF are the main growth factors involved in chon-
drogenic differentiation. The TGF-β super-family includes 
the proteins which play an important role in the formation of 
cartilage. The family members including TGF-β, bone mor-
phogenetic proteins (BMPs), inhibins and activins regulate 
cell growth, differentiation, and apoptosis of different cell 
types including osteoblasts, chondrocytes, neural and epi-
thelial cells (77). The FGF family regulates the proliferation, 
differentiation, and matrix production of articular cartilage 
and growth plate chondrocytes both in vivo and in vitro (78). 
In IGF family, IGF-1 mediates chondrogenesis by increasing 
the production of proteoglycan and collagen type II (79). 
As previously reported, combination of TGF-β3 and IGF-1 
elevates chondrogenic induction from human mesenchymal 
stem cell (80). Longobardi et al (81) evaluated the effects of 
IGF-1 on the chondrogenesis of bone marrow mesenchymal 
stem cells in either presence or absence of TGF-β signalling. 
They found that IGF-1 modulates the mesenchymal stem cell 
chondrogenesis by stimulating the proliferation, regulating cell 
apoptosis and inducing the expression of chondrocyte mark-
ers. Application of IGF-1 and TGF-β1 in a bioreactor elevates 
the compressive and tensile biomechanical properties of the 
engineered tissue (82). Furthermore, combination of growth 
factors promotes the efficiency of chondrocyte proliferation 
in the automated bioreactors (83). It has been shown that in-
corporating of growth factors into the scaffold material results 
in chondrocyte differentiation, tissue growth, and integration 
with native cartilage tissue. Chitosan scaffolds associated 
with chondrogenic differentiation factor, BMP-6, have been 
successfully used in the engineering of articular cartilage (84). 
In the field of bone regeneration, the concept of a bone-
generating protein was first popularized by Urist when he 
discovered the BMPs, the most popular molecules for bone 
tissue engineering (85). The common osteogenic factors are 
the members of TGF-β superfamily including TGF-β1, BMP-
2, BMP-7, and retinoic acid (86,87). VEGF has also been 
identified as an osteogenic factor (88). Likewise, FGF-2 is 
proposed as the most appropriate growth factor for inducing 
the osteogenic differentiation of mesenchymal stem cells. Its 
supportive role in ex vivo expansion of osteogenic precur-
sors from human bone marrow was reported (89). In general, 
osteoinduction may be caused by various factors such as 
pre-seeded osteoblasts and/or bioactive molecules incorpo-
rated into a polymer scaffold. Following the degradation, a 
polymer scaffold releases the incorporated growth factor with 
defined kinetics leading to the recruitment and differentiation 
of mesenchymal progenitor cells localized in the neighbor-
ing original bone tissue (90). Engineering of osteoinductive 
grafts may be achieved by loading the 3D scaffolds with either 
BMPs or osteogenic cells. Bone matrix is a 3D scaffold for 
bone cells that besides providing a tissue-specific environment 
and architecture, serves as a reservoir of water, nutrients, 
cytokines, and growth factors for the bone cells. The most 
important non-collagenous organic constituents of bone matrix 
are the multi-functional proteins including osteocalcin, bone 
sialoprotein, osteopontin and osteonectin that are produced 
by bone cells and regulate bone mineralization and remodel-
ling. Bone matrix contains several growth factors including 
FGFs, IGFs, PDGF, and TGF-β superfamily. These growth 
factors are implicated in the regulation of cell proliferation 
and differentiation as well as endochondral bone formation 
(91). The local concentration of growth factor affects the lev-
els of differentiation of osteoblasts. The rapid diffusion and 
clearance of TGF-β2 from the implant site may be overcome 
by binding of TGF-β2 to bovine dermal fibrillar collagen via 
polyethylene glycol that result in the enhancement of growth 
factor stability and bioactivity (92). 
Regarding growth factor delivery in bone regeneration, it 
has been primarily focused on the poly(α-hydroxy acid) fam-
ily of polymers. Microparticles of gelatin and poly(α-hydroxy 
acid) have been used for growth factor delivery (74). In animal 
models of bone defects, basic fibroblast growth factor (bFGF) 
incorporated within the cross-linked gelatin hydrogels has 
shown therapeutic potential (93,94). 
In hepatic tissue engineering, studying the molecular signals 
that regulate the proliferation and function of hepatocytes is 
an attractive research area. In this sense, hepatotropic factors 
including epidermal growth factor (EGF), acidic fibroblastic 
growth factor (aFGF), hepatocyte growth factor/scatter factor 
(HGF/SF), and TGF-α have attracted a growing interest (95). 
Hepatocytes transplanted within a synthetic degradable poly-
mer should remain viable with retention of their differentiated 
phenotype. Poly(D,L-lactic-co-glycolic acid) microparticles 
containing EGF co-transplanted with hepatocytes in poly-
(vinyl alcohol)-coated poly(L-lactic acid) scaffolds enhanced 
the engraftment of hepatocytes (96). An adequate vasculari-
sation at the transplantation site is essential. The exogenous 
growth factor-induced prevascularization of the implant site 
due to the delivery of endothelial cell growth factor (ECGF) 
from chitosan-albumin microspheres enhances the survival of 
hepatocytes (97). The involvement of FGF for an appropriate 
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vascularization of the transplant has been shown (98). 
Growth factors are also implicated in the tissue engineer-
ing of skin. PDGF, TGF-α, TGF-β, and b-FGF are the major 
constituents of bioengineered products for the treatment of a 
variety of chronic skin wounds, venous ulcers, or diabetic foot 
ulcers (99,100). Regarding the implication of growth factors 
in the tissue-engineered myocardium, nanofiber scaffolds in-
cluding VEGF has been shown to create a microenvironment 
for arteriogenesis and cardiac repair (101). Moreover, HGF-
transfected skeletal myoblasts limit the development of post-
infarction heart failure (102). In corneal tissue-engineering, 
TGF-β3 has been shown to regulate the assembly of a non-
fibrotic matrix in a 3D corneal model (103) and EGF is a major 
constituent of tissue-engineered cornea (104). 
GROWTH FACTORS AND BIOMATERIALS 
The regularly applied biomaterials in tissue engineering are 
solid synthetics or hydrogel-type substances (105). Matrigel, 
an extracellular matrix which contains laminin, fibronectin and 
proteoglycans, stimulates cell proliferation and preserves the 
typical morphological features of olfactory ensheathing cells, 
Schwann cells, and bone marrow stromal cells. Besides the 
promoting of neuronal growth in dorsal root ganglia, matrigel 
serves as a scaffold for in vivo delivery of Schwann cells (106). 
Purified Schwann cells were mixed with matrigel and inserted 
in semipermeable non-degradable polyacrylonitrile/polyvi-
nylchloride (PAN/PVC) copolymer guidance channels (107). 
This construct was used to bridge a transected rat spinal cord 
and the following electrophysiological evaluation confirmed 
the functionality of regenerating axons. The combination of 
matrigel with VEGF or a replication-defective adenovirus cod-
ing for VEGF decreased the retrograde degeneration of axons 
in the corticospinal tract and increased axonal regenerative 
activities in rats (108). Moreover, implantation of matrigel-
contained PAN/PVC guidance channels which are enriched 
with GDNF promotes axonal regeneration and myelination 
following SCI (109). 
The fibrous aggregates of plasma fibronectin, an extracel-
lular matrix which is involved in a variety of cellular processes 
including the tissue repair, embryogenesis, blood clotting, 
and cell migration/adhesion (110), have been used to make 
fibronectin mats which contain pores oriented in a single di-
rection. Incubation of fibronectin mats with BDNF and NT-3 
increases the neurofilament-positive and glutaminergic fibres. 
Moreover, incorporation of NGF into these mats elevates the 
number of calcitonin gene-related peptide (CGRP)-positive 
neurons (111). Implantation of fibronectin mats impregnated 
with NT-3 after the transection of sciatic nerve in rat, promoted 
the regeneration of peripheral nerves and neuromuscular 
interaction (112). 
Alginate, a linear polysaccharide, has been used as a scaf-
fold to fill the cavity in the damaged spinal cord because of 
its biocompatibility, hydrophilicity, and low toxicity (113). 
Alginate sponge as a 3D scaffold is beneficial for the trans-
plantation of hippocampus-derived neurosphere cells into the 
injured spinal cord in rat (114). BDNF-producing fibroblasts 
encapsulated within alginate contributed to the functional 
recovery after SCI (115). Microencapsulation of fibroblasts 
producing BDNF in alginate-poly-L-ornithine is another 
method for application of alginate in the treatment of SCI. Mi-
crocapsules protect fibroblasts from the host immune response, 
therefore, eliminate the need for immunosuppressive therapy 
(116). Microencapsulation preserves the biological activity 
of growth factors as well. In the case of microencapsulation, 
BDNF and NGF retain their biological activity for at least 30 
days (117,118). 
Application of the water-soluble surfactant polyethylene 
glycol (PEG) to the site of injury in the spinal cord has been 
shown to seal and repair the breaches in cell membrane, re-
verse the injury-induced permeabilization of the membrane, 
inhibit the production of free radicals, and reduce the oxidative 
stress (119-121). The conjugation of growth factors with PEG 
improves their plasma pharmacokinetics and facilitates the 
transport of growth factors across the BBB (122,123). FGF 
and VEGF may be covalently or noncovalently bound to a 
variety of materials including PEG to induce the prolifera-
tion, differentiation, adhesion, and spreading of embryonic 
stem cells (124).
Among the bioengineered products, fibrin-based scaffolds 
have gained increasing popularity. Fibrin which acts as a 
natural matrix for tissue regeneration, is non-toxic and biode-
gradable and enhances the effects of cell-scaffold constructs. 
Interestingly, fibrin may be produced using a patient’s own 
blood supply. Fibrin gels may be used in neural or cardiovas-
cular tissue engineering (125-127). In the area of peripheral 
nerve regeneration, the performance of fibrin-based scaffolds 
is enhanced due to the incorporation of bFGF which promotes 
nerve extension (128). Meanwhile, fibrin is usually enriched 
with aFGF. Fibrin containing aFGF has been applied to the 
both ends of Schwann cells/matrigel cables in PAN/PVC 
guidance channels leading to the enhancement of sprouting 
in the corticospinal tracts (129). Synthetic hydrogels such as 
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poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) 
(PHEMA/ PHEMA-MMA) tubes with excellent mechanical 
integrity, have induced nerve regeneration when filled with fi-
brin and FGF-1 (130). Implantation of PHEMA sponge into the 
cavity of the injured spinal cord has shown axonal re-growth 
after contusion SCI in rat (131). Moreover, inclusion of growth 
factors within the PHEMA-MMA hydrogel guidance channels 
improved specific supraspinal and local axonal regeneration 
after the transection of spinal cord (132). 
In an attempt to fabricate nerve guidance scaffolds, freeze-
dried agarose scaffolds containing NGF have been shown to 
promote axonal regeneration following SCI (133). In addi-
tion, collagen gels may be used for the localized delivery of 
therapeutic agents after SCI. Subarachnoid-injected collagen 
gels deliver growth factors leading to the proliferation of 
progenitor cells in the injured spinal cord (134). The combina-
tion of collagen gels with NT-3 or BDNF have been shown to 
stimulate the regeneration of axons in the corticospinal tract 
and promote functional recovery in rat model of spinal cord 
transaction (135,136). Moreover, grafts of poly(D,L-lactic 
acid) scaffolds impregnated with BDNF enhance the axonal 
regeneration of transected spinal cord (137). In recent years, 
poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA), linear 
and water-swellable cross-linked polymers, have been devel-
oped for drug delivery or gene therapy (138). Combination 
of BDNF- and CNTF-producing fibroblasts with PHPMA 
hydrogel grafts promotes axonal re-growth following brain 
injury in rat (139). The capacity of multifunctional growth 
factor CNTF to rescue axotomized motoneurons and pre-
vent their degeneration has been shown in animal models of 
degenerative motoneuron disorders (141,142). raising hope 
that CNTF may be used for the treatment of patients with de-
generative motoneuron disorders such as amyotrophic lateral 
sclerosis (ALS). In this respect, clinical studies on the patients 
with ALS started, however, the initial encouraging reports 
could not be consolidated and the presence of side effects 
including cachexia, fever, and reactivation of herpes simplex 
virus resulted in the termination of clinical trials (143-145). 
In addition, subcutaneously administered CNTF accumulate 
preferentially in the liver, therefore, the systemic application 
of CNTF is unlikely to make it optimally available in motor 
neuron diseases. Based on the tissue engineering strategies, 
CNTF or CNTF-secreting genetically-engineered cells may be 
microencapsulated that depending on the method of encapsula-
tion and choice of polymer, the biologically active CNTF will 
be available for different periods of times. Microencapsulated 
CNTF has been shown to promote neuronal survival and 
nerve outgrowth in the cultures of ciliary ganglia, indicating 
its biological stability. Moreover, microencapsulated CNTF 
may offer a less invasive and effective mode of delivery than 
permanently installed cannulae. According to the relatively 
small dimensions of microspheres containing CNTF, they 
can be injected intrathecally, thereby, avoiding toxic effects 
of CNTF in the liver (146). 
Delivery of growth factors
A growth factor which is released from a delivery device may 
influence the regeneration of damaged tissue or enhance the 
engraftment and function of co-delivered cells. Meanwhile, 
the type of growth factor, dosage, and release profile should be 
optimized for an efficient delivery. Regarding the mechanisms 
of release, a growth factor directly incorporated into a biore-
sorbable polymer scaffold is released by a diffusion-controlled 
mechanism (147). Alternatively, the growth factor delivery 
device in the form of microparticles, nanoparticles, fibers 
or injectable complexes can be incorporated into a suitable 
scaffold. A growth factor may also be released by an erosion 
mechansim or a combination of diffusion and erosion (148). 
Hydrogel formulations have been presented for the localized 
delivery of growth factors. Matrix metalloproteinase (MMP)-
sensitive hydrogels may be used for the targeted release of 
growth factors such as VEGF which improves the vasculariza-
tion in the engineered constructs (149,150). Controlled release 
of growth factors that is essential for a variety of tissue engi-
neering applications, may be achieved by different methods 
such as delivery from polymeric microspheres, discs, mini-
pumps or transplanted cells. In this context, polymer matrices 
such as poly(-ethylene-co-vinyl acetate) and microparticles 
of poly(D,L-lactic-co-glycolic acid) have been developed 
(151,152). The nanoporous peptide particles which are used 
for encapsulating and releasing of growth factors, are consid-
ered as a promising therapeutic approach in neurodegenera-
tive disorders (153). Combination of cell transplantation and 
growth factor delivery for the treatment of neurodegenerative 
diseases has been proposed (154). In addition, macrocapsules 
prepared by filling the preformed poly(acryonitrile-co-vinyl 
chloride) hollow fibre tubular structures with cells, have been 
used as a continuous source of growth factors for the treatment 
of neurodegenerative diseases (155). Further, NGF prevents 
the degeneration of dopaminergic neurons and slows down the 
progression of Parkinson’s disease (156,157); however, NGF 
similar to other neurotrophic factors does not significantly 
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penetrate the BBB. Therefore, the clinical significance of NGF 
will depend on the application of a suitable carrier system 
which enhances NGF transport across the BBB. A number of 
studies have shown that drug delivery to the brain is consid-
erably enhanced by prior binding of the drug to poly(butyl 
cyanoacrylate) (PBCA) nanoparticles that are overcoated 
with polysorbate-80 (158,159). Polysorbate 80-coated PBCA 
nanoparticles have been proposed as an effective carrier system 
for NGF transport across the BBB following the intravenous 
injection. This approach may improve the effectiveness of 
NGF-based therapy in age-related neurodegenerative diseases 
(160). At present, the therapeutic potential of VEGF-loaded 
PBCA nanoparticles in an experimental model of traumatic 
brain injury is evaluated in our laboratory. Conjugation of NGF 
with dextran has been shown to improve the penetration of 
NGF into the brain and elevates its retention (161). In addi-
tion, conjugation of NGF with PEG (PEGylation) is another 
means by which the stability and effectiveness of NGF are 
enhanced (162). Encapsulation of PEGylated VEGF into the 
polysorbate-80 coated PBCA nanoparticles as the drug delivery 
system as well as the evaluation of VEGF release profile and 
its biological activity are currently performed in our laboratory. 
Growth factors and cell therapy
Cell therapy, a sub-type of regenerative medicine, is based 
on the introducing of cells into a tissue in order to treat 
a disease. It has been found to initiate the restoration of 
neurological cells in the damaged site and facilitate cogni-
tive function. In animal models of SCI, application of the 
olfactory ensheathing cells; the glial cells ensheathing the 
axons of the olfactory receptor neurons, has resulted in the 
spinal cord repair (163,164). The regenerative capability of 
olfactory ensheathing cells is mainly due to the secretion 
of growth factors such as VEGF, NGF, BDNF, and GDNF 
(165,166). Implantation of activated macrophages results 
in the partial recovery in paraplegic rats (167). Moreover, 
activated macrophages improve motor recovery and reduce 
spinal cyst formation in the experimental model of SCI (168). 
The increased production of BDNF appears to be involved 
in the neuroregenerative potential of macrophages (169). 
Following SCI, the remyelinating capability of Schwann 
cells and the functionality of the myelin in the conduction of 
neural impulses have been demonstrated (170,171). Schwann 
cells promote axonal regeneration by secretion of adhesion 
molecules, extracellular matrix, and a number of growth 
factors such as FGF-2, NGF, BDNF, and NT-3 (172-174). 
Following the transection of rat spinal cord, combination of 
cultured Schwann cells with FGF-1, NT-3 or BDNF induces a 
remarkable anatomical connectivity and functional recovery 
in severed axons (175). Transplanted Schwann cells within 
the semipermeable poly(acryonitrile-co-vinyl chloride) 
polymer tubes which are used as guides for peripheral nerve 
regeneration, promoted neuronal regeneration when BDNF 
and NT-3 were infused simultaneously (176). Genetically 
modified NGF-secreting neural stem cells survived and ac-
quired phenotypic characteristics of early nerve cells when 
grafted into the injured adult rat brain (177). Moreover, the 
regenerative effects of encapsulated cells secreting NGF have 
been reported (178,179). Likewise, NGF delivered from the 
polymer-encapsulated genetically-modified baby hamster 
kidney cells (BHK) promotes the survival of axotomized 
septal cholinergic neurons (180). In addition, BHK cells have 
been genetically modified to secrete GDNF or CNTF for the 
treatment of Parkinson’s disease (181) and ALS (182,183). In 
recent years, the knowledge of adipobiology has recognized 
the adipose tissue as the major endocrine and paracrine organ 
of the human body (184). Based on the regenerative potential 
of adipose-derived stem cells (ADSC), neurodegenerative 
(185,186) and cardiovascular (187) diseases may be targets 
for ADSC-based therapies.
CONCLUSION
The recent advances in tissue engineering have resulted in 
the development of a novel set of tissue repair or replacement 
strategies. The remarkable advances in stem cells research, 
biomimetic environments, biomaterials, and growth factors 
have created unique opportunities to combine the specialized 
cells with engineered extracellular matrices and biologically 
active molecules in order to fabricate tissues. There are strong 
links between the tissue engineering and drug delivery systems. 
Experiments have shown that growth factors delivered from a 
device promote the engraftment and function of co-delivered 
cells and regeneration of damaged tissues. In this context, 
there is an increasing interest for the development of more 
sophisticated growth factor delivery mechanisms in order to 
mimic the endogenous profiles of growth factor production 
during natural tissue morphogenesis or regeneration. A major 
challenge in tissue engineering is the need for more function-
ality and biomechanical stability in laboratory-grown tissues 
destined for transplantation. Further evidence for the develop-
ment of intelligent biomaterials delivering growth factors to 
the injured tissue are expected.   
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